A phase I study of a second generation clusterin antisense oligonucleotide (OGX-011) in combination with docetaxel
Phase of Trial: Phase I
Latest Information Update: 28 Mar 2016
At a glance
- Drugs Custirsen (Primary) ; Docetaxel
- Indications Bladder cancer; Breast cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 21 Sep 2013 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 10 Feb 2006 New trial record.